IsomAb

IsomAb is a UK-based biotech advancing isoform-specific antibodies to tackle diseases with few or no treatment options. Founded as a University of Nottingham spin-out, its lead candidate, ISM-001, targets VEGF-A 165 b to enhance angiogenesis and improve outcomes for patients with peripheral arterial disease and type 2 diabetes.